Kairos Pharma reported asset growth of 13.38% for the quarter ended Dec 2025. These growth metrics cover 8 quarters of results from Dec 2023 through Dec 2025, standardized by Business Quant from the company’s SEC filings.
| Growth Metrics | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Dec2025 |
|---|---|---|---|---|---|---|---|---|
| Growth Ratios | ||||||||
| Assets Growth (1y) | 497.72% | 13.38% | ||||||
| Assets (QoQ) | 15.27% | 37.60% | -15.93% | |||||
| Cash & Equivalents Growth (1y)Cash & Equiv. Growth (1y) | 3,149.49% | 1,267.74% | 253.07% | |||||
| Cash & Equivalents (QoQ)Cash & Equiv. (QoQ) | -6.06% | -60.46% | 184.28% | -16.10% | ||||
| Cash from Operations Growth (1y)Cash from Ops. Growth (1y) | -2,831.82% | -2,083.33% | -379.17% | |||||
| Cash from Operations (QoQ)Cash from Ops. (QoQ) | -45.45% | -566.67% | -1,102.38% | 10.74% | 60.40% | -12.75% | ||
| EBIT Growth (1y) | -33.45% | -32.78% | -341.11% | -555.86% | ||||
| EBIT (QoQ) | -279.44% | 73.65% | 22.65% | -72.52% | -277.55% | 12.45% | -15.01% | |
| EBT Growth (1y) | -204.64% | -44.60% | -316.50% | -507.69% | ||||
| EBT (QoQ) | -261.59% | 72.25% | 22.77% | -293.16% | -71.63% | 20.08% | -12.68% | |
| EPS (Basic) Growth (1y) | -188.56% | -32.20% | -177.12% | -272.91% | ||||
| EPS (Basic) (QoQ) | -259.91% | 72.73% | 22.77% | -280.64% | -64.89% | 42.83% | -3.92% | |
| EPS (Diluted) Growth (1y) | -188.56% | -32.20% | -177.12% | -272.91% | ||||
| EPS (Diluted) (QoQ) | -259.91% | 72.73% | 22.77% | -280.64% | -64.89% | 42.83% | -3.92% | |
| Free Cash Flow Growth (1y)FCF Growth (1y) | -2,831.82% | -2,083.33% | -379.17% | |||||
| Free Cash Flow (QoQ)FCF (QoQ) | -45.45% | -566.67% | -1,102.38% | 10.74% | 60.40% | -12.75% | ||
| Interest Coverage Ratio Growth (1y)Interest Cover Growth (1y) | 96.27% | 97.00% | ||||||
| Interest Coverage Ratio (QoQ)Interest Cover (QoQ) | -1,797.21% | 95.06% | -3.14% | 96.14% | -1,424.38% | |||
| Net Cash Flow Growth (1y)NCF Growth (1y) | -32,316.67% | 4,522.64% | -2,963.16% | |||||
| Net Cash Flow (QoQ)NCF (QoQ) | -783.33% | 64.15% | 16,921.05% | -160.86% | 220.51% | -124.83% | ||
| Net Income Growth (1y) | -204.64% | -44.60% | -316.50% | -507.69% | ||||
| Net Income (QoQ) | -261.59% | 72.25% | 22.77% | -293.16% | -71.63% | 20.08% | -12.68% | |
| Net Income towards Common Stockholders Growth (1y)Net Income Growth (1y) | -204.64% | -44.60% | -316.50% | -507.69% | ||||
| Net Income towards Common Stockholders (QoQ)Net Income (QoQ) | -261.59% | 72.25% | 22.77% | -293.16% | -71.63% | 20.08% | -12.68% | |
| Operating Income Growth (1y)Op. Inc Growth (1y) | -33.45% | -32.78% | -341.11% | -555.86% | ||||
| Operating Income (QoQ)Op. Inc (QoQ) | -279.44% | 73.65% | 22.65% | -72.52% | -277.55% | 12.45% | -15.01% | |
| Profit After Tax Growth (1y)PAT Growth (1y) | -235.58% | 12.34% | -290.71% | -462.06% | ||||
| Profit After Tax (QoQ)PAT (QoQ) | -258.33% | 71.11% | 21.67% | -313.83% | 6.40% | -28.78% | -12.68% | |
| Return on Assets [ROA] (QoQ)ROA (QoQ) | -193.00 | -1265.00 | ||||||
| Return on Capital Employed [ROCE] (QoQ)ROCE (QoQ) | -164.00 | -1380.00 |